Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis
- 10 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (1) , 149-153
Abstract
In RA, the relationship between autoantibody status and treatment response to MTX remains unclear. We investigated the association between autoantibody status and early remission in newly diagnosed RA patients treated with MTX using real-world data. RA-patients initially treated with MTX were selected from an international observational database (METEOR). Patients were stratified into autoantibody-positive (RF- and/or ACPA-positive) or autoantibody negative (RF- and ACPA-negative). The effect of autoantibody status on the chance of achieving remission within 3 to 6 months was analysed using Cox-proportional hazards regression. Data from 1826 RA patients were available for analysis. DAS remission was achieved in 17% (318/1826). This was similar in autoantibody-positive [17% (282/1629)] and -negative patients [18% (36/197)]. Hence, autoantibody positivity was not associated with remission [hazard ratio (HR) 0.89, 95% CI 0.57, 1.38]. Similar findings were found when stratified for MTX monotherapy (HR 0.75, 95% CI 0.41, 1.37) or combination treatment (HR 0.76, 95% CI 0.37, 1.54). Good physical function (HAQ < 0.5) was achieved in 33% (530/1590) of all patients. Autoantibody-positivity was also not associated with HAQ < 0.5 (HR 1.05, 95% CI 0.71, 1.57). Autoantibody status is not associated with early remission in newly diagnosed RA-patients receiving MTX. This indicates that MTX is effective as an initial treatment strategy regardless of autoantibody status.Keywords
This publication has 19 references indexed in Scilit:
- Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan‐European Registry AnalysisArthritis & Rheumatology, 2016
- Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysisAnnals of the Rheumatic Diseases, 2013
- Predictors for remission in rheumatoid arthritis patients: A systematic reviewArthritis Care & Research, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progressionAnnals of the Rheumatic Diseases, 2005
- Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisArthritis Research & Therapy, 2005
- A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow upAnnals of the Rheumatic Diseases, 2005
- Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)Annals of the Rheumatic Diseases, 2004
- Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factorsRheumatology, 1999